{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Longeveron Mesenchymal Stem Cells",
            "NStudiesAvail": 430108,
            "NStudiesFound": 8,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 8,
            "FieldList": [
                  "DesignTimePerspective",
                  "DesignWhoMasked",
                  "DetailedDescription",
                  "DispFirstPostDate",
                  "DispFirstPostDateType",
                  "DispFirstSubmitDate",
                  "DispFirstSubmitQCDate",
                  "EligibilityCriteria",
                  "EnrollmentCount",
                  "EnrollmentType",
                  "EventGroupDeathsNumAffected",
                  "EventGroupDeathsNumAtRisk",
                  "EventGroupDescription",
                  "EventGroupId",
                  "EventGroupOtherNumAffected",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Investigator",
                              "Outcomes Assessor"
                        ],
                        "DetailedDescription": [
                              "The objectives of this study are to assess safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) compared to placebo on 1) functional mobility and exercise tolerance, 2) patient-reported physical function, and 3) the inflammatory cytokine biomarker tumor necrosis factor (TNF-alpha)."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nBe willing and able to provide written informed consent and comply with all procedures required by the Protocol.\nBe >70 and < 85 years of age at the time of signing the Informed Consent Form.\nHave a Canadian Study on Health and Aging (CSHA) Clinical Frailty Scale score of 5 \"mildly frail\" or 6 \"moderately frail\".\nHave a 6 minute walk distance of > 200m and < 400 m. Distances of two 6MWTs are to be within 15% of each other.\nHave a serum TNF-alpha level > 2.5 pg/mL\n\nExclusion Criteria:\n\nBe unwilling or unable to perform any of the assessments required by the protocol.\nHave a diagnosis of any disabling neurologic disorder, including, but not limited to, Parkinson's disease, Amyotrophic Lateral Sclerosis, multiple sclerosis, cerebrovascular accident with residual deficits (e.g., muscle weakness or gait disorder), or diagnosis of dementia.\nHave a score of 24 or lower on the Mini Mental State Examination (MMSE)\nHave poorly controlled blood glucose levels (HbA1c >8.0%).\nHave a clinical history of malignancy within 2.5 years (i.e., subjects with prior malignancy must be cancer free for 2.5 years) except curatively-treated basal cell carcinoma, melanoma in situ or cervical carcinoma.\nHave any condition that in the opinion of the Principal Investigator limits lifespan to < 1 year.\nHave autoimmune disease (e.g. rheumatoid arthritis, systemic lupus erythematosus).\nBe using chronic immunosuppressant therapy such as high-dose corticosteroids or TNF-alpha antagonists (prednisone use at doses of < 5 mg daily is allowed).\n\nTest positive for hepatitis B virus\n\na. If the subject tests positive for anti-hepatitis B core antigen (HBc) or anti-HBs, they must be currently receiving treatment for Hepatitis B prior to infusion and remain on treatment throughout the study.\n\nTest positive for verimic Hepatitis C virus, HIV1/2, or syphilis\nHave a resting blood oxygen saturation of <93% (measured by pulse oximetry).\nKnown or suspected alcohol or drug abuse within three years preceding Screening\nHave a known hypersensitivity to dimethyl sulfoxide (DMSO).\nBe an organ transplant recipient (other than transplantation for corneal, bone, skin, ligament, or tendon).\nBe actively listed (or expected future listing) for transplant of any organ (other than corneal transplant).\n\nHave any clinically important abnormal screening laboratory values, including, but not limited to:\n\nHemoglobin <10.0 g/dL,\nWhite blood cell <2,500/ul, or platelet count <100,000/ul\nLiver dysfunction evidenced by enzymes (AST and ALT) > 3 times the upper limit of normal (ULN)\nCoagulopathy (INR>1.3) not due to a reversible cause (e.g. warfarin and/or Factor Xa inhibitors).\nUncontrolled hypertension (resting systolic blood pressure >180 mm Hg or diastolic blood pressure of > 110 mm Hg at Screening)\nHave unstable angina pectoris, uncontrolled or severe peripheral artery disease within the previous 3 months.\nHave congestive heart failure defined by NYHS (New York Heart Association) Class III or IV, or an ejection fraction of <25%.\nHave a coronary artery bypass surgery, angioplasty, or peripheral vascular disease revasculation or a myocardial infarction within previous 3 months.\nHave severe pulmonary dysfunction: acute exacerbation of chronic obstructive lung disease stage III or IV (Gold classification), and/or PaO2 levels <60 mmHg.\nHave a partial ileal gastric bypass, or other significant intestinal malabsorption.\nHave advanced liver or renal disease\nHave cognitive or language barriers that prohibit obtaining informed consent or any study elements.\nBe currently hospitalized, or living in an assisted living facility or a long-term care facility.\nBe currently participating (or participated within the previous 30 days of consent) in an investigational therapeutic or device trial.\nHave a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study."
                        ],
                        "EnrollmentCount": [
                              "150"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT03169231"
                        ]
                  },
                  {
                        "Rank": 2,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Care Provider",
                              "Investigator",
                              "Outcomes Assessor"
                        ],
                        "DetailedDescription": [
                              "This is a randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) or placebo in subjects with Alzheimer's Disease. Following a successful Safety Run-In Phase, a total of twenty-five (25) subjects will be randomized to (2:2:1) to receive low-dose LMSCs, high-dose LMSCs or placebo. After randomization, baseline imaging, and study product infusion, subjects will be followed up at 2,4,13, 26, 39 and 52 week post study product infusion. Intention-to-treat study population will be used for the purpose of the endpoint analysis and safety evaluations."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria: All subjects enrolled in this trial must:\n\nprovide written informed consent;\nbe 50 - 80 years of age at the time of signing the Informed Consent form;\nhave a body mass of 45 - 150 kg;\nat the time of enrollment, be diagnosed with AD in accordance with the NINCDS-AA criteria;\nscore between 18 and 24 on the Mini Mental State Examination (MMSE);\nhas one (or more) identified adult caregiver who is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for \u22652 hours/day \u22653 days/week; and agrees to accompany the subject to each study visit;\nblood oxygen saturation \u226593% determined via pulse oximetry;\nhave a brain MRI consistent with AD;\nhave a PET scan using an FDA-approved tracer (e.g., AMYViD, Vizamyl, or Neuraceq), and which indicates the presence of beta-amyloid plaques in the cerebral cortex, within 5 years of enrollment;\nhave normal levels of thyroid hormone (free T4) and thyroid-stimulating hormone (TSH);\nhave normal levels of B12 and folate;\nhave a designated study partner who will accompany the subject to all clinic visits and participate in the subject's clinical assessments; or\nbe living in the community, including in an assisted living facility, but excluding long-term care nursing facilities.\n\nExclusion Criteria: All subjects enrolled in this trial must not:\n\nbe unable to perform any of the assessments required for endpoint analysis;\nshow signs of dementia other than AD, such as from AIDS (Acquired Immunodeficiency Syndrome), CJD (Creutzfeldt-Jakob disease), LBD (Lewy Bodies dementia), CVD (Cerebrovascular dementia), PSP (Progressive Supranuclear Palsy), MCI (multiple cerebral infarctions) or NPH (normal pressure hydrocephalus);\nhave any other neurodegenerative disease;\nhave a history of a seizure disorder;\nhave clinically important abnormal screening laboratory values beyond AD;\nhave any conditions that would contraindicate an MRI, such as the presence metallic objects in the eyes, skin, or heart;\nhave any conditions that would contraindicate a PET scan;\nhave > 4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as \"possible\" or \"definite\"), a single area of superficial siderosis, or evidence of a prior macrohemorrhage as assessed by MRI;\nbe currently using corticosteroids or similar powerful steroidal anti-inflammatory medication (e.g., Prednisone) on a regular basis (exceptions allowed include regular use of steroidal nasal sprays, topical steroids, and estrogen-replacement therapy);\nbe active listed (or expected to be listed) for transplant of any organ;\nbe an organ transplant recipient;\nhave a known hypersensitivity to dimethyl sulfoxide (DMSO).\nhave a condition that is projected to limited life expectancy to < 1 year.\nhave a sitting or resting systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg at Screening;\nhave a history of alcohol or drug abuse within the past 5 years.\nhave been diagnosed with malignancy within the past 5 years, with the exception of curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma;\nbe a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraception (female subjects must undergo a urine pregnancy test at screening and on the infusion day prior to infusion);\nhave any serious illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study;\nhave any serious illness or any other condition that, in the opinion of the investigator, may compromise the validity of the study (e.g., signs of stroke, traumatic brain injury (TBI), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinsonism;\nhave participated in any investigational therapeutic or device trial within the past 5 years that the investigator feels would influence or affect the outcome of the study;\nbe currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial;\nbe positive for HIV, Syphilis and Hepatitis C; or\nbe positive for Hepatitis B. If the subject tests positive for anti-HBc or anti-HBs, subject must be currently receiving treatment for hHepatitis B prior to infusion and remain on treatment throughout the study."
                        ],
                        "EnrollmentCount": [
                              "33"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT02600130"
                        ]
                  },
                  {
                        "Rank": 3,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Investigator"
                        ],
                        "DetailedDescription": [
                              "This study is designed to assess the safety, tolerability, and efficacy of Lomecel-B (formerly LMSCs) as an adjunct therapy to the standard stage II (BDCPA) surgical intervention for HLHS, which is typically performed at 4 - 6 months after birth. Lomecel-B will be delivered via intramyocardial injections.\n\nA total of 30 patients will be enrolled in 2 stages with 3 Cohorts.\n\nIn the first stage, 10 consecutive HLHS patients will be enrolled and treated with LMSCs (Cohort A). The first 3 patients will be treated no less than 5 days apart, and will be evaluated for any treatment-emergent adverse events (TE-AEs) (e.g., induced myocardial infarction or perforation). These patients will undergo full evaluation for 5 days to demonstrate safety prior to proceeding with the remainder of the cohort. After 6 months post-treatment of the last patient of Cohort A, a formal safety review will be conducted prior to proceeding to the next phase.\n\nThe second stage is double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with LMSCs (Cohort B, 10 patients), or will receive no cells and no injection (Cohort C, 10 patients)."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria: all patients must have HLHS (all types) requiring BDCPA surgery.\n\nExclusion Criteria: all patients must not have any of the following.\n\nSignificant coronary artery sinusoids.\nRequirement for mechanical circulatory support prior to BDCPA surgery.\nUnderlying evidence of arrhythmia requiring anti-arrhythmia therapy.\nNeed for concomitant surgery for aortic coarctation or tricuspid valve repair.\nHLHS and restrictive or intact atrial septum.\nUndergoing the Stage I (Norwood) procedure that does not have HLHS.\nSerum positivity for: HIV; hepatitis B virus surface antigen (HBV BsAg); and/or viremic hepatitis C virus (HCV).\nParent/guardian that is unwilling or unable to comply with necessary follow-up.\nUnsuitability for the study based on the Investigator's clinical opinion.\nDocumented chromosomal abnormalities"
                        ],
                        "EnrollmentCount": [
                              "10"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT03525418"
                        ]
                  },
                  {
                        "Rank": 4,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Investigator"
                        ],
                        "DetailedDescription": [
                              "A pilot phase will consist of a 3 subject safety run-in, followed by 20 subject randomized phase to evaluate influenza vaccine response at 1 week and 4 weeks post infusion of Lomecel-B (Formerly LMSCs). This will be followed by a double-blinded, randomized, placebo-controlled phase."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nbe willing and able to provide written informed consent and comply with all procedures required by the protocol.\nbe 65 - 90 years of age at the time of signing the Informed Consent Form.\nhave a diagnosis of Aging Frailty, with a score of 4 to 7 using the Canadian Frailty Scale.\nhave a six-minute walk test (6MWT) distance of 200m - 400m for each of 2 trials, and the 2 trials must be within 15% of each other.\nhave total bilirubin between 0.3 - 1.9 mg/dL.\n\nExclusion Criteria:\n\nbe unwilling or unable to perform any of the assessments required by the Protocol.\nscore \u226424 on the Mini Mental State Examination (MMSE).\nhave previously received current year's flu-vaccine.\nhave any contraindication to receiving a vaccine.\nhave a Hemoglobin A1c (HbA1c) level >9.0%.\nbe diagnosed with malignancy (subjects without a recurrence in the last 2.5 years will be allowed) except curatively-treated basal cell carcinoma, melanoma in situ, or cervical carcinoma.\nhave a condition that projected to limit the life-expectancy to \u22641 year.\nhave autoimmune disease (e.g., rheumatoid arthritis).\nbe using medication(s) known to alter immune response, e.g., high-dose corticosteroids.\nhave HIV, AIDS, or other immunodeficiency.\n\ntest positive for hepatitis B virus\n\nIf the subject tests positive for anti-HBc or anti-HBs, they must be receiving treatment for Hepatitis B virus prior to infusion and remain on treatment throughout the study.\ntest positive for viremic hepatitis C, HIV1, HIV2, or syphilis.\nhave a resting blood oxygen saturation of <93% (measured by pulse oximetry).\nbe a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraception.\nhave documented current substance and/or alcohol abuse.\nhave known allergies to latex or eggs.\nhave a known hypersensitivity to dimethyl sulfoxide (DMSO).\nbe an organ transplant recipient (other than corneal, bone, skin, ligament, or tendon transplant).\nbe actively listed (or expected to be listed) for transplant of any organ (other than corneal, bone, skin, ligament, or tendon transplant).\n\nhave any clinically important abnormal screening laboratory values, including but not limited to:\n\nhemoglobin <10.0 g/dL.\nwhite blood cell count < 2500/mm3.\nplatelets < 100,000/mm3.\nprothrombin time/international normalized ratio (PT/INR) \u02c3 1.5 not due to a reversible cause (i.e. Coumadin).\naspartate transaminase, alanine transaminase, or alkaline phosphatase \u02c3 2 times upper limit of normal.\nhave a sitting or resting systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg at Screening.\nhave any serious illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study, or that may compromise the validity of the study.\nbe currently participating in an investigational therapeutic or device trial, or have participated in an investigational therapeutic or device trial within the previous 30 days, or participate in any other clinical trial for the duration of the time that the subject actively participates in this trial."
                        ],
                        "EnrollmentCount": [
                              "62"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT02982915"
                        ]
                  },
                  {
                        "Rank": 5,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Care Provider",
                              "Investigator",
                              "Outcomes Assessor"
                        ],
                        "DetailedDescription": [
                              "This is a randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) in subjects with metabolic syndrome and to assess the effects of LMSCs on endothelial function using several different doses. Following a successful run-in phase, a total of forty (40) subjects will be randomized (1:1:1:1) to receive one of three different doses of LMSCs or placebo. After randomization, baseline imaging, testing and study product infusion, subjects will be followed up at 24 hours, month 1, month 3, month 6, month 9 and month 12 post study product infusion. All endpoints will be assessed at the 3, 6 and 12 month visits which will occur 90\u00b130 days, 180\u00b130 days, and 365\u00b130 days respectively from the day of the study product infusion (Day 1). For the purposes of the endpoint analysis and safety evaluations, an \"intent-to-treat\" study population will be utilized."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nEach subject must provide written informed consent.\nEach subject must be \u226545 and \u2264 85 years of age at the time of signing the Informed Consent Form.\nEach subject must have endothelial dysfunction.\n\nAt the time of enrollment, each subject must meet at least 3 out of the 5 criteria under the harmonized definition of the metabolic syndrome, consisting of the following\n\nHypertension.\nElevated triglycerides.\nReduced high-density lipoprotein (HDL) levels.\nElevated fasting glucose. --Central obesity.\n\nExclusion Criteria:\n\nBe unable and/or unwilling to perform any of the assessments required for endpoint analysis.\nHave diabetic retinopathy.\nSitting or resting systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg at Screening.\nHave a resting blood oxygen saturation of <93% (measured by pulse oximetry).\nBe hypersensitive to dimethyl sulfoxide (DMSO).\nHave a history of alcohol or drug abuse within the past 24 months.\nHave been diagnosed with malignancy within the past 5 years, with the exception of curatively-treated basal cell carcinoma, melanoma in situ or cervical carcinoma.\nBe an organ transplant recipient.\nBe actively listed (or expected to be listed) for transplant of any organ.\nHave a condition that limits life expectancy to < 1 year.\nBe serum positive for HIV, hepatitis B sAG or viremic hepatitis C.\nBe a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraception (female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection).\nHave any serious comorbid illness or other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.\nBe currently participating in an investigational therapeutic or device trial.\nBe currently participating in an investigational therapeutic or device trial, or have participated in an investigational therapeutic or device trial within the previous 30 days, or participate in any other clinical trial for the duration of the time that he or she is actively participating in this trial."
                        ],
                        "EnrollmentCount": [
                              "40"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT02587572"
                        ]
                  },
                  {
                        "Rank": 6,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Investigator"
                        ],
                        "DetailedDescription": [
                              "Double-blinded, randomized, placebo-controlled study with 2 cohorts.\n\nCohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million Lomecel-B Arm 2: 10 subjects treated with up to 3 doses of Placebo.\n\nCohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million Lomecel-B Arm 4: 10 subjects treated with up to 3 doses of Placebo.\n\nEach subject will be intravenously infused with 100 million Lomecel-B (formerly LMSCs) or placebo on Day 0. If no treatment-related AEs are seen after the infusion, a second infusion will be given on Day 3. If no treatment-related AEs are seen after the second infusion, a third infusion will be given Day 6.\n\nFollow-up visits will be conducted: daily until hospital discharge; at Week 4 after treatment (with LMSCs or placebo) for patients already discharged; and at Month 6 after treatment (with LMSCs or placebo)."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nMale or female or any race or ethnicity.\nAt least 18 years of age.\nProvide written informed consent. For subjects who are incapable of providing informed consent, written informed consent can be provided on behalf of the subject by a legally authorized representative (LAR).\n\nDiagnosis of mild to severe ARDS per the Berlin Definition of ARDS. More specifically, the following 3 conditions must be present.\n\nA need for positive pressure ventilation by an endotracheal or tracheal tube with a PaO2/FiO2 ratio < 200 with at least 8 cm H2O positive end-expiratory airway pressure (PEEP). A patient may be included if the PaO2/FiO2 ratio < 200 with < 8 cm H2O PEEP if there is a contraindication to increased PEEP (evidence of barotrauma).\nBilateral infiltrates consistent with pulmonary edema on frontal chest radiograph.\nNo clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.\nConfirmed diagnosis of infection with coronavirus or influenza virus.\nWilling to perform all assessments required for the study.\nMust agree to the collection of all blood samples per protocol.\nMust agree to have samples stored and used for secondary research.\n\nExclusion Criteria:\n\nPatient receiving Extracorporeal Membrane Oxygenation (ECMO).\nHistory of malignancy within previous 2.5 years, except for curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ, or cervical carcinoma.\n\nPrior positive test for any of the following without demonstration of resolution.\n\ni. Hepatitis B virus (HBV) surface antigen (HBsAg). ii. Viremic hepatitis C virus (HCV). iii. Human immunodeficiency virus-1 or -2 (HIV1 or 2 HIV2). iv. Human T-cell leukemia virus-I or -II (HTLV-I or HTLV-II). v. Syphilis.\n\nFemale who is pregnant, nursing, or of childbearing potential while not practicing effective contraception.\nKnown hypersensitivity to dimethyl sulfoxide (DMSO).\nBe an organ transplant recipient, other than for corneal, bone, skin, ligament, or tendon transplant.\nActively listing (or expected listing) for transplant of any organ, other than for corneal, bone, skin, ligament, or tendon transplant.\nContinuous use of any medication at immunosuppressive dosing for greater than 14 consecutive days over the past 3 months.\nCurrently participating in an investigational therapeutic or device trial, or have participated in an investigational therapeutic or device trial within the previous 30 days, or participate in any other clinical trial for the duration of the time that the subject actively participates in this trial. However, use of hydroxychloroquine, remdesivir, lopinavir/ritonavir and ivermectin are allowed as well as convalescent plasma.. Exceptions for other experimental interventions related to treating the patient's acute illness may be made with prior approval of Longeveron.\nAny serious comorbid illness or any other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study, or that may compromise the validity of the study."
                        ],
                        "EnrollmentCount": [
                              "70"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04629105"
                        ]
                  },
                  {
                        "Rank": 7,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "This is an open label study, intended as a safety and efficacy assessment prior to a full comparator study. In this Phase I study, cells administered will be delivered in 6-10 intramyocardial injections that will be tested in 20 patients and 10 patients will be controls with a total of 30 HLHS patients.\n\nA total of 30 patients with HLHS will be enrolled in a staged enrollment process. In this open-labeled study, a maximum of 20 patients will eventually receive intramyocardial injection of the allogeneic mesenchymal stem cells and 10 control patients with no cell injection. The enrollment of the patients will occur in two stages groups: Group A and Group B. In Group A, 10 consecutive HLHS patients will be initially enrolled in the allogenic MSCs treatment arm to determine feasibility and safety. After 6 months of the last enrolled patient in Group A, all Group A patients will be assessed in order to determine whether it is feasible and safe, including the harvesting, processing, and administering of the allogeneic MSCs. Thereafter, Group B will start enrolling a total of 20 HLHS patients which will be randomized to the treatment and control arms in a 1:1 ratio, respectively, in order to have 10 allogeneic MSCs-treated patient and 10 control patients. At the completion of this Phase I clinical study, the total enrolled cohort will be 20 patients treated with allogeneic MSCs and 10 patients in the control arm."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubjects with hypoplastic left heart syndrome (all types) requiring BDCPA surgery.\n\nExclusion Criteria:\n\nHave HLHS and restrictive or intact atrial septum.\nBe undergoing the Norwood procedure that do not have HLHS.\nHave significant coronary artery sinusoids.\nRequire mechanical circulatory support prior to surgery.\nHave an underlying evidence of arrhythmia requiring anti-arrhythmia therapy.\nParent or guardian unwilling or unable to comply with necessary follow-up(s)\nBe serum positive for HIV, hepatitis BsAg (B Surface Antigen) or viremic hepatitis C.\nBe unsuitable for inclusion in the study, in the opinion of the investigator.\nNeed for concomitant surgery for aortic coarctation or tricuspid valve repair."
                        ],
                        "EnrollmentCount": [
                              "5"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT02398604"
                        ]
                  },
                  {
                        "Rank": 8,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Investigator"
                        ],
                        "DetailedDescription": [],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nProvide written informed consent.\nSubjects age greater than or equal to 60 and less than or equal to 95 years at the time of signing the Informed Consent Form.\nShow signs of frailty apart from a concomitant condition as assessed by the Investigator with a frailty score of 4 to 7 using the Clinical Frailty Scale\nFemale subjects with an Follicle-stimulating hormone (FSH) equal to or > 25.8 milli-international units (mIU) /mL (milliliter), if not currently on hormone replacement therapy.\n\nExclusion Criteria:\n\nScore of less than or equal to 24 on the Mini Mental State Examination (MMSE)\nInability to perform any of the assessments required for endpoint analysis (report safety or tolerability concerns, perform pulmonary function tests, undergo blood draws, read and respond to questionnaires.\nActive listing (or expected future listing) for transplant of any organ.\nClinically important abnormal screening laboratory values, including but not limited to: hemoglobin <8 g/dl, white blood cell count <3000/mm3, platelets<80,000/mm3, international normalized ratio (INR) > 1.5 not due to a reversible cause (i.e. Coumadin), aspartate transaminase, alanine transaminase, or alkaline phosphatase > 3 times upper limit of normal, total bilirubin > 1.5 mg/dl.\nSerious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study. Including, but not limited to: HIV, advanced liver or renal failure, class III/IV congestive heart failure, myocardial infarction, unstable angina, or cardiac revascularization within the last six months, or severe obstructive ventilatory defect.\nAny other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.\nBe an organ transplant recipient.\nHave a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma if recurrence occurs.\nHave a non-pulmonary condition that limits lifespan to < 1 year.\nHave a history of drug or alcohol abuse within the past 24 months.\nBe serum positive for HIV, hepatitis B Surface Antigen (BsAg) or Viremic hepatitis C.\nBe currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.\nBe a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion.\nHave hypersensitivity to dimethyl sulfoxide (DMSO)"
                        ],
                        "EnrollmentCount": [
                              "65"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [
                              "0",
                              "0",
                              "1",
                              "0",
                              "1",
                              "0",
                              "1"
                        ],
                        "EventGroupDeathsNumAtRisk": [
                              "5",
                              "5",
                              "5",
                              "10",
                              "10",
                              "10",
                              "20"
                        ],
                        "EventGroupDescription": [
                              "Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
                              "Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
                              "Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
                              "Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
                              "Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
                              "Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion\n\nPlacebo: Placebo administered by peripheral intravenous infusion.",
                              "Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion\n\nPenicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion."
                        ],
                        "EventGroupId": [
                              "EG000",
                              "EG001",
                              "EG002",
                              "EG003",
                              "EG004",
                              "EG005",
                              "EG006"
                        ],
                        "EventGroupOtherNumAffected": [
                              "0",
                              "0",
                              "0",
                              "0",
                              "0",
                              "0",
                              "0"
                        ],
                        "NCTId": [
                              "NCT02065245"
                        ]
                  }
            ]
      }
}